Gene Therapy for CNS Summit – What’s it About?
The Gene Therapy for CNS Summit is set to unite key leaders across the gene therapy space, focused on targeting the CNS to treat important neurodegenerative disorders. You can expect to meet C-Level Leaders, Directors, Vice Presidents, Heads, and Scientists all within discovery, research, translational development, clinical development, and regulatory affairs.
This is a must-attend meeting to ensure you are networking with like-minded colleagues facing the same daily challenges surrounding vector development, BBB crossing, identifying accurate CNS models and more – to jointly overcome them and move the needle forward on gene therapy development.
Download the Brochure to Explore Sessions Covering the Focus Areas Outlined Above
❝
Hanson Wade creates a very immersive environment at these summits which, along with a high quality of speakers, makes for very comfortable and productive networking
Sue Brown, Chief Scientific Officer, Passage Bio
❞
Key Focus Areas of The Agenda:
Optimizing Capsid Delivery
Find the right capsid to successfully deliver your gene therapy to the brain and reduce off-target toxicities with Novartis
Advancing BBB Penetration
Analyze novel engineered AAV capsids that bind to BBB receptors to improve clinical translation with Affinia Therapeutics
Enhancing Design with AI
Understand the nuances of machine-guided design of AAV capsids to improve pan-brain efficacy with Dyno Therapeutics
Expanding Patient Reach
Target the giants of neurodegenerative diseases and widen your patient pool with Sanofi
Scaling Vector Technologies
Understand the hurdles in scaling up vector technologies to prevent upstream manufacturing setbacks with Ultragenyx
Who Will You Meet?
Have more specific questions about attending companies or their sessions?
Download the full brochure here or email us directly at info@hansonwade.com — we’re happy to help!